Sep 13, 2017 7:30am EDT ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer's Disease
Jul 05, 2017 7:30am EDT ProMIS Neurosciences to Present Preclinical Data from Alzheimer's Disease Program at AAIC 2017
Jun 06, 2017 7:30am EDT ProMIS™ Neurosciences Appoints William C. Mobley to Scientific Advisory Board
May 31, 2017 7:30am EDT ProMIS Neurosciences Identifies Novel Therapeutic Epitope Target for ALS and Dementia
May 25, 2017 7:30am EDT Prion 2017: Deciphering Neurodegenerative Disorders - 23-26 May 2017 Edinburgh
May 24, 2017 7:30am EDT ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer's Disease